Health Outcomes of Patients With Acute Coronary Syndromes Prescribed Ticagrelor in UK Primary Care: a Retrospective Cohort Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 1,650
- 主要终点
- Incidence of all cause death in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
研究概览
简要总结
Cohort study using data from Clinical Practice Research Datalink (CPRD). The study cohort includes all patients who received at least one prescription for ticagrelor for the first time between December 2010 and March 2015, following ACS. Patient baseline characteristics will be described: (Age, Gender, Body Mass Index, Smoking status, Sociodemographic status), type of ACS and interventions, CV history and comorbidities, bleeding and respiratory history.
The following outcomes will be examined: Incidence of vascular events (composite MI, Stroke, vascular death, specific vascular event and all cause death), incidence of bleeding and incidence of dysponea. Time to event for vascular events, bleeding and dyspnoea.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •First prescription (index date) for ticagrelor between Dec 2010 and Mar 2015
- •At least 12 months history in database prior to first ticagrelor prescription
- •Linkage to Hospital Episode Statistics (HES)
- •Acute Coronary Syndrome (ACS) event in the three months prior to and including the index date
排除标准
- •Primary care prescription for clopidogrel or prasugrel between the ACS date and the index date
结局指标
主要结局
Incidence of all cause death in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
时间窗: From index date up to 12 months
Incidence of vascular death in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
时间窗: From index date up to 12 months
Time to event for composite outcome of myocardial infarction (MI), Stroke or death from vascular causes in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
时间窗: From index date up to 12 months
Time to event for all cause death in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
时间窗: From index date up to 12 months
Incidence of myocardial infarction (MI) in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
时间窗: From index date up to 12 months
Incidence of composite outcome of myocardial infarction (MI), Stroke or death from vascular causes in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
时间窗: From index date up to 12 months
Incidence of stroke in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
时间窗: From index date up to 12 months
Time to event for myocardial infarction (MI) in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
时间窗: From index date up to 12 months
Time to event for stroke in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
时间窗: From index date up to 12 months
Time to event for vascular death in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
时间窗: From index date up to 12 months
次要结局
- Time to event for bleeding in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)(From index date up to 12 months)
- Incidence of bleeding in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)(From index date up to 12 months)
- Time to event for dyspnoea in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)(From index date up to 12 months)
- Incidence of dyspnoea in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)(From index date up to 12 months)